Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Floxacillin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : SignaTope GmbH, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Flucloxacillin as an Inducer of CYP-enzymes
Details : Flucloxacillin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 12, 2021
Lead Product(s) : Floxacillin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : SignaTope GmbH, Germany
Deal Size : Inapplicable
Deal Type : Inapplicable